Haemonetics Co. (NYSE:HAE) – Equities researchers at Jefferies Financial Group decreased their Q3 2019 EPS estimates for shares of Haemonetics in a research report issued to clients and investors on Tuesday, November 6th. Jefferies Financial Group analyst A. Petrone now anticipates that the medical instruments supplier will earn $0.58 per share for the quarter, down from their prior estimate of $0.59. Jefferies Financial Group has a “Buy” rating and a $125.00 price objective on the stock. Jefferies Financial Group also issued estimates for Haemonetics’ FY2019 earnings at $2.30 EPS, FY2020 earnings at $3.40 EPS, FY2021 earnings at $4.35 EPS and FY2022 earnings at $5.20 EPS.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The business had revenue of $241.58 million during the quarter, compared to analysts’ expectations of $233.44 million. Haemonetics had a return on equity of 16.04% and a net margin of 2.26%. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the firm posted $0.48 EPS.

HAE has been the subject of several other reports. Morgan Stanley lifted their price objective on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, August 8th. Barrington Research lifted their price objective on Haemonetics from $90.00 to $118.00 and gave the company an “outperform” rating in a report on Thursday, August 9th. Zacks Investment Research raised Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price objective for the company in a report on Friday, October 12th. Finally, TheStreet cut Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. Haemonetics has a consensus rating of “Buy” and an average target price of $113.20.

NYSE:HAE opened at $111.61 on Thursday. The company has a market cap of $5.95 billion, a P/E ratio of 52.31, a PEG ratio of 3.67 and a beta of 1.09. The company has a quick ratio of 1.94, a current ratio of 2.92 and a debt-to-equity ratio of 0.47. Haemonetics has a 1-year low of $53.74 and a 1-year high of $117.56.

In other news, Director Pedro P. Granadillo sold 30,824 shares of Haemonetics stock in a transaction on Monday, September 17th. The stock was sold at an average price of $111.83, for a total value of $3,447,047.92. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO William P. Mr. Burke sold 841 shares of Haemonetics stock in a transaction on Thursday, October 25th. The shares were sold at an average price of $46.76, for a total value of $39,325.16. The disclosure for this sale can be found here. Insiders sold a total of 62,653 shares of company stock valued at $6,973,391 over the last ninety days. Insiders own 1.04% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. CIBC Asset Management Inc bought a new position in shares of Haemonetics in the 3rd quarter valued at $219,000. Wagner Bowman Management Corp bought a new position in shares of Haemonetics in the 2nd quarter valued at $224,000. Arjuna Capital bought a new position in shares of Haemonetics in the 2nd quarter valued at $224,000. Granahan Investment Management Inc. MA bought a new position in shares of Haemonetics in the 2nd quarter valued at $229,000. Finally, Wealth Alliance Advisory Group LLC bought a new position in shares of Haemonetics in the 3rd quarter valued at $229,000. Institutional investors own 96.44% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading: Understanding Market Liquidity

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.